Home

Download

Statistics

Landscape

Help

Contact

	1. Gene summary of enriched editing regions
	2. Tumor-specific enriched editing regions
	Comparison of enriched editing regions between tumor and normal.
	Correlation of enriched editing regions with tumor stages.
	Associations of enriched editing regions with cancer survival.
	3. Enriched editing regions and immune related genes
	4. Enriched editing regions and immune related splicing
	5. Enriched editing regions and immune infiltration
	6. Enriched editing regions and immune gene sets
	Correlation of enriched editing regions with epithelial-mesenchymal transition.
	Correlations of enriched editing regions with hypoxic.
	Associations of enriched editing regions with hallmark gene sets from MSigDB.
	7. Enriched editing regions and drugs
	Correlations between enriched editing regions and drug sensitivity.
	Enriched editing regions targeted by drugs from DrugBank database.

Editing gene: PECAM1 (ImmuneEditome ID:5175)

1. Gene summary of enriched editing regions for PECAM1

Gene summary

Gene information	Gene symbol	PECAM1
	Gene ID	5175
	GeneSynonyms	CD31\|CD31/EndoCAM\|GPIIA'\|PECA1\|PECAM-1\|endoCAM
	GeneCytomap	17q23.3
	GeneType	protein-coding
	GeneDescription	platelet endothelial cell adhesion molecule\|CD31 antigen\|platelet endothelial cell adhesion molecule-1
	GeneModificationdate	20230417
	UniprotID	P16284;A0A075B728;A0A075B727;A0A075B737
	PubMed ID

UCSC image.

Locations of each EERs.

EER	ENST	ENSG	GeneName	Region	Repeat	dsRNA structure
chr17:64321487-64323046:-	ENST00000563924.4	ENSG00000261371.4	PECAM1	UTR3	AluSq,AluSx,AluJb	chr17:64321487-64323046:-.alignment

Top

2. Tumor-specific enriched editing regions for PECAM1

Comparison of enriched editing regions between tumor and normal.

* P<0.05 and Informative number >=20.

* EER: enriched editing region, EAG: EER-associated genes.

ID_events	cancer	Type	P	Boxplot
chr17:64321487-64323046:-	COAD	EER	8.3842e-06
ENSG00000261371.4,PECAM1	COAD	EAG	8.3842e-06

Top

Correlation of enriched editing regions with tumor stages.

* AnovaP<0.05, Pearson P<0.05 and Informative number >=20.

* EER: enriched editing region, EAG: EER-associated genes, Path: Pathological stage, Cli: Clinical stage.

* Only shows the most significant correlation result of EERs/EAGs with either pathological stage or clinical stage according to correlation coefficient (R). For more results, please go to download page.

ID_events	cancer	Type	StageType	AnovaP	P	R	Boxplot
chr17:64321487-64323046:-	BLCA	Path	EER	4.4593e-07	9.0232e-04	-0.1747
ENSG00000261371.4,PECAM1	BLCA	Path	EAG	4.4593e-07	9.0232e-04	-0.1747
chr17:64321487-64323046:-	LUSC	Path	EER	1.5083e-02	2.6280e-03	-0.1400
ENSG00000261371.4,PECAM1	LUSC	Path	EAG	1.5083e-02	2.6280e-03	-0.1400
ENSG00000261371.4,PECAM1	PAAD	Path	EAG	1.0812e-02	2.2562e-02	0.1749
chr17:64321487-64323046:-	PAAD	Path	EER	1.0812e-02	2.2562e-02	0.1749

Top

Associations of enriched editing regions with cancer survival.

* Pkm<0.05 and Pcox<0.05.

* EER: enriched editing region, EAG: EER-associated genes.

ID_events	cancer	TypeID	Pkm	Pcox_continuous	HR_continuous	KMPlot
ENSG00000261371.4,PECAM1	CHOL	EAG	2.8202e-02	5.8997e-03	2.4886e+15

Top

3. Enriched editing regions and immune related genes for PECAM1

Enriched editing regions and immune related genes.

* First, the associations between enriched editing regions and genes were tested by QTL and Pearson method (QTL: FDR<0.05 and Pearson: P<0.05).

* Second, the gene relationships with immune were tested by three analyses: whether the gene is an immune gene (InnateDB、Immport、Immunome、Immunogenetic Related Information Source (IRIS)), whether the gene is associated with immune infiltration and whether the gene is related to immune gene sets.

* EER: enriched editing region, EAG: EER-associated genes.

* Only shows the most significant correlation result of genes with the fraction of different immune cells and the scores of 50 hallmark genesets according to correlation coefficient (R). For more results, please go to download page.

ID_events

cancer

Type

Gene

beta

FDR

PearsonP

PearsonR

CorrelationPlot

RBP

RBPtargets

ImmuneGene

ImmuneFraction

HallMark

chr17:64321487-64323046:-

BLCA

EER

ENSG00000186260,MKL2

0.2252

4.7585e-04

2.5235e-19

0.4520

CELF2;DHX9;DKC1;EIF4A3;ELAVL1;FBL;FUS;HNRNPA1;HNRNPC;HNRNPD;HNRNPK;IGF2BP2;KHDRBS2;KHDRBS3;METTL3;MSI1;NOP56;NOP58;PCBP2;PTBP1;QKI;RBFOX2;RBM47;SRSF1;TAF15;TARDBP;U2AF2;YTHDC1

T_cells_CD4_memory_resting

GSVA_HALLMARK_REACTIVE_OXYGEN_SPECIES_PATHWAY

chr17:64321487-64323046:-

BLCA

EER

ENSG00000075975,MKRN2

0.1865

4.2575e-03

1.4715e-30

0.5583

DHX9;DKC1;EIF4A3;ELAVL1;FBL;FUS;HNRNPA1;HNRNPC;HNRNPD;HNRNPK;IGF2BP2;KHDRBS2;KHDRBS3;MSI1;MSI2;NOP56;NOP58;PCBP2;PTBP1;QKI;RBFOX2;RBM47;SRSF1;TAF15;TARDBP;U2AF2;YTHDC1

Macrophages_M1

GSVA_HALLMARK_P53_PATHWAY

chr17:64321487-64323046:-

BLCA

EER

ENSG00000113249,HAVCR1

0.1444

2.4834e-02

2.2533e-15

0.4035

EIF4A3;FBL;FUS;HNRNPA1;HNRNPC;IGF2BP2;MSI1;NOP56;NOP58;PTBP1;TAF15;U2AF2

HAVCR1

T_cells_CD4_memory_resting

GSVA_HALLMARK_KRAS_SIGNALING_DN

chr17:64321487-64323046:-

BLCA

EER

ENSG00000132155,RAF1

0.1384

4.2672e-02

1.0454e-29

0.5514

CELF2;DHX9;DKC1;EIF4A3;ELAVL1;FBL;FUS;HNRNPA1;HNRNPC;HNRNPD;HNRNPK;IGF2BP2;KHDRBS2;KHDRBS3;METTL3;MSI1;MSI2;NOP56;NOP58;PCBP2;PTBP1;QKI;RBFOX2;RBM47;SRSF1;TAF15;TARDBP;U2AF2;YTHDC1

RAF1

GSVA_HALLMARK_P53_PATHWAY

chr17:64321487-64323046:-

GBM

EER

ENSG00000129925,TMEM8A

0.3166

9.1419e-03

1.6809e-07

0.4234

CELF2;DKC1;EIF4A3;ELAVL1;FBL;FUS;HNRNPA1;HNRNPC;HNRNPK;IGF2BP2;KHDRBS2;METTL3;MSI1;MSI2;NOP56;NOP58;PCBP2;PTBP1;RBFOX2;SRSF1;TAF15;TARDBP;U2AF2;YTHDC1

TMEM8A

T_cells_regulatory_(Tregs)

GSVA_HALLMARK_APICAL_JUNCTION

More results

Top

4. Enriched editing regions and immune related splicing for PECAM1

Enriched editing regions and immune related splicing.

* First, the associations between enriched editing regions and splicing events were tested by QTL and Pearson method (QTL: FDR<0.05 and Pearson: P<0.05).

* Second, the splicing relationships with immune were tested by three analyses: whether the splicing event locates in an immune gene (InnateDB、Immport, Immunome and Immunogenetic Related Information Source (IRIS)), whether the splicing event is associated with immune infiltration and whether the splicing event is related to immune gene sets.

* EER: enriched editing region, EAG: EER-associated genes.

* Only shows the most significant correlation result of splicing events with the fraction of different immune cells and the scores of 50 hallmark genesets according to correlation coefficient (R). For more results, please go to download page.

ID_events

cancer

Type

SplicingType

SplicingGene

SplicingChr

SplicingPosition

beta

FDR

PearsonP

PearsonR

CorrelationPlot

RBP

RBPtargets

ImmuneGene

ImmuneFraction

HallMark

ENSG00000261371.4,PECAM1

BLCA

EAG

ENSG00000107262.12

chr9

33261086:33261169:33262104:33262235:33262072:33262235

-0.0406

3.6754e-02

1.5869e-22

-0.4942

BAG1

Dendritic_cells_activated

GSVA_HALLMARK_MITOTIC_SPINDLE

chr17:64321487-64323046:-

BLCA

EER

ENSG00000107262.12

chr9

33261086:33261169:33262104:33262235:33262072:33262235

-0.0406

3.2378e-02

1.5869e-22

-0.4942

CELF2;DKC1;EIF4A3;ELAVL1;FBL;FUS;HNRNPA1;HNRNPC;HNRNPK;IGF2BP2;MSI1;MSI2;NOP56;NOP58;PCBP2;PTBP1;RBFOX2;SRSF1;TAF15;TARDBP;U2AF2;YTHDC1

BAG1

Dendritic_cells_activated

GSVA_HALLMARK_MITOTIC_SPINDLE

More results

Top

5. Enriched editing regions and immune infiltration for PECAM1

Associations of enriched editing regions with immune infiltration.

* P<0.05 and Informative number >=20.

* EER: enriched editing region, EAG: EER-associated genes.

* Only shows the most significant correlation result of EERs/EAGs with the fraction of different immune cells according to correlation coefficient (R). For more results, please go to download page.

ID_events	cancer	TypeID	ImmuneCell	P	R	CorrelationPlot
chr17:64321487-64323046:-	BLCA	EER	Macrophages_M1	4.1890e-03	-0.1514
ENSG00000261371.4,PECAM1	BLCA	EAG	Macrophages_M1	4.1890e-03	-0.1514
chr17:64321487-64323046:-	BRCA	EER	T_cells_CD4_memory_resting	3.3303e-03	0.0917
ENSG00000261371.4,PECAM1	BRCA	EAG	T_cells_CD4_memory_resting	3.3350e-03	0.0917
chr17:64321487-64323046:-	CESC	EER	Monocytes	5.6487e-06	0.2805
ENSG00000261371.4,PECAM1	CESC	EAG	Monocytes	5.6487e-06	0.2805
ENSG00000261371.4,PECAM1	CHOL	EAG	Mast_cells_activated	2.6922e-02	0.3972
chr17:64321487-64323046:-	COAD	EER	Macrophages_M1	6.4650e-03	-0.1732
ENSG00000261371.4,PECAM1	COAD	EAG	Macrophages_M1	6.4650e-03	-0.1732
ENSG00000261371.4,PECAM1	DLBC	EAG	B_cells_naive	6.3259e-03	0.4100
chr17:64321487-64323046:-	ESCA	EER	T_cells_regulatory_(Tregs)	1.2579e-02	0.2047
ENSG00000261371.4,PECAM1	ESCA	EAG	T_cells_regulatory_(Tregs)	1.1940e-02	0.2062
chr17:64321487-64323046:-	GBM	EER	Macrophages_M0	3.7291e-03	0.2427
ENSG00000261371.4,PECAM1	GBM	EAG	Macrophages_M0	3.7291e-03	0.2427
chr17:64321487-64323046:-	HNSC	EER	Dendritic_cells_resting	1.4482e-02	0.1143
ENSG00000261371.4,PECAM1	HNSC	EAG	Dendritic_cells_resting	1.4482e-02	0.1143
chr17:64321487-64323046:-	KIRC	EER	Macrophages_M2	1.8467e-02	0.1205
ENSG00000261371.4,PECAM1	KIRC	EAG	Macrophages_M2	1.7392e-02	0.1216
chr17:64321487-64323046:-	KIRP	EER	T_cells_CD4_memory_resting	3.2039e-03	0.1846
ENSG00000261371.4,PECAM1	KIRP	EAG	T_cells_CD4_memory_resting	3.2039e-03	0.1846
chr17:64321487-64323046:-	LAML	EER	Mast_cells_activated	2.7614e-02	0.1862
ENSG00000261371.4,PECAM1	LAML	EAG	Mast_cells_activated	3.8604e-02	0.1750
chr17:64321487-64323046:-	LGG	EER	Macrophages_M2	1.3893e-03	-0.1490
ENSG00000261371.4,PECAM1	LGG	EAG	Macrophages_M2	1.3893e-03	-0.1490
chr17:64321487-64323046:-	LIHC	EER	Monocytes	1.4548e-02	-0.1318
ENSG00000261371.4,PECAM1	LIHC	EAG	Monocytes	1.4548e-02	-0.1318
chr17:64321487-64323046:-	LUAD	EER	Eosinophils	2.8819e-02	0.1000
ENSG00000261371.4,PECAM1	LUAD	EAG	Eosinophils	2.8892e-02	0.1000
chr17:64321487-64323046:-	LUSC	EER	T_cells_regulatory_(Tregs)	1.3024e-02	-0.1157
ENSG00000261371.4,PECAM1	LUSC	EAG	T_cells_regulatory_(Tregs)	1.3024e-02	-0.1157
chr17:64321487-64323046:-	OV	EER	B_cells_memory	1.5530e-03	0.2126
ENSG00000261371.4,PECAM1	OV	EAG	B_cells_memory	1.5949e-03	0.2121
chr17:64321487-64323046:-	PAAD	EER	Macrophages_M2	1.6195e-03	0.2386
ENSG00000261371.4,PECAM1	PAAD	EAG	Macrophages_M2	1.6195e-03	0.2386
chr17:64321487-64323046:-	READ	EER	Plasma_cells	1.9693e-02	0.2469
ENSG00000261371.4,PECAM1	READ	EAG	Plasma_cells	1.9693e-02	0.2469
chr17:64321487-64323046:-	SARC	EER	T_cells_CD4_memory_activated	8.6767e-03	0.1705
ENSG00000261371.4,PECAM1	SARC	EAG	T_cells_CD4_memory_activated	8.6767e-03	0.1705
chr17:64321487-64323046:-	THCA	EER	T_cells_CD4_memory_activated	4.2588e-02	0.0916
ENSG00000261371.4,PECAM1	THCA	EAG	T_cells_CD4_memory_activated	4.2588e-02	0.0916
ENSG00000261371.4,PECAM1	THYM	EAG	Dendritic_cells_resting	4.6982e-03	-0.2765
chr17:64321487-64323046:-	UCS	EER	Mast_cells_activated	1.4584e-03	0.4424
ENSG00000261371.4,PECAM1	UCS	EAG	Mast_cells_activated	1.4584e-03	0.4424
ENSG00000261371.4,PECAM1	UVM	EAG	Macrophages_M1	1.6458e-02	-0.3281

Top

6. Enriched editing regions and immune gene sets for PECAM1

Correlation of enriched editing regions with epithelial-mesenchymal transition.

* First, the differences of enriched editing regions between Epi and Mes groups (defined by KS-test) were compared (P<0.05 and Informative number >=20).

* Second, the correlations between enriched editing regions and gene set score of HALLMARK_EPITHELIAL_MESENCHYMAL_TRANSITION were analyzed (P<0.05 and Informative number >=20).

* EER: enriched editing region, EAG: EER-associated genes.

* Only shows the EERs/EAGs significantly edited between Epi and Mes group.

ID_events

cancer

Type

E2M_P

Boxplot

CorP

CorR

CorrelationPlot

Top

Correlations of enriched editing regions with hypoxic.

* First, there are four hypoxia scores used in the database. The first three hypoxic scores were calculated on three gene sets of Buffa, Ragnum and Winter based on one previous study (PMID: 32024819). One last hypoxia score was defined on HALLMARK_HYPOXIA by GSVA method.

* Second, the correlations enriched editing regions with the four hypoxic scores were analyzed (P<0.05 and Informative number >=20).

* EER: enriched editing region, EAG: EER-associated genes.

* Only shows the EERs/EAGs significantly correlated with all four hypoxia gene set scores. For more results, please go to download page.

ID_events

cancer

Type

Buffa_P

Buffa_R

Ragnum_P

Ragnum_R

Winter_P

Winter_R

HALLMARK_P

HALLMARK_R

CorrelationPlot

Top

Associations of enriched editing regions with hallmark gene sets from MSigDB.

* P<0.05 and Informative number >=20.

* EER: enriched editing region, EAG: EER-associated genes.

* Only shows the most significant correlation result of EERs/EAGs with the scores of 50 hallmark genesets according to correlation coefficient (R). For more results, please go to download page.

ID_events	cancer	HallmarkType	Type	P	R	CorrelationPlot
chr17:64321487-64323046:-	BLCA	GSVA_HALLMARK_KRAS_SIGNALING_DN	EER	1.4556e-02	-0.1294
ENSG00000261371.4,PECAM1	BLCA	GSVA_HALLMARK_KRAS_SIGNALING_DN	EAG	1.4556e-02	-0.1294
ENSG00000261371.4,PECAM1	BRCA	GSVA_HALLMARK_UV_RESPONSE_DN	EAG	5.5428e-03	0.0867
chr17:64321487-64323046:-	BRCA	GSVA_HALLMARK_UV_RESPONSE_DN	EER	5.5499e-03	0.0866
ENSG00000261371.4,PECAM1	CESC	GSVA_HALLMARK_UV_RESPONSE_UP	EAG	1.7210e-04	-0.2336
chr17:64321487-64323046:-	CESC	GSVA_HALLMARK_UV_RESPONSE_UP	EER	1.7210e-04	-0.2336
ENSG00000261371.4,PECAM1	CHOL	GSVA_HALLMARK_ANGIOGENESIS	EAG	2.1051e-02	0.4127
ENSG00000261371.4,PECAM1	COAD	GSVA_HALLMARK_UV_RESPONSE_UP	EAG	4.3631e-04	-0.2226
chr17:64321487-64323046:-	COAD	GSVA_HALLMARK_UV_RESPONSE_UP	EER	4.3631e-04	-0.2226
chr17:64321487-64323046:-	ESCA	GSVA_HALLMARK_IL6_JAK_STAT3_SIGNALING	EER	4.9333e-02	0.1619
ENSG00000261371.4,PECAM1	ESCA	GSVA_HALLMARK_IL6_JAK_STAT3_SIGNALING	EAG	4.6937e-02	0.1636
ENSG00000261371.4,PECAM1	GBM	GSVA_HALLMARK_APICAL_JUNCTION	EAG	7.2573e-03	0.2252
chr17:64321487-64323046:-	GBM	GSVA_HALLMARK_APICAL_JUNCTION	EER	7.2573e-03	0.2252
chr17:64321487-64323046:-	HNSC	GSVA_HALLMARK_ANDROGEN_RESPONSE	EER	1.7957e-03	0.1457
ENSG00000261371.4,PECAM1	HNSC	GSVA_HALLMARK_ANDROGEN_RESPONSE	EAG	1.7957e-03	0.1457
chr17:64321487-64323046:-	KIRC	GSVA_HALLMARK_REACTIVE_OXYGEN_SPECIES_PATHWAY	EER	8.2462e-03	-0.1350
ENSG00000261371.4,PECAM1	KIRC	GSVA_HALLMARK_REACTIVE_OXYGEN_SPECIES_PATHWAY	EAG	7.6300e-03	-0.1363
chr17:64321487-64323046:-	KIRP	GSVA_HALLMARK_INTERFERON_ALPHA_RESPONSE	EER	1.7735e-02	-0.1490
ENSG00000261371.4,PECAM1	KIRP	GSVA_HALLMARK_INTERFERON_ALPHA_RESPONSE	EAG	1.7735e-02	-0.1490
ENSG00000261371.4,PECAM1	LIHC	GSVA_HALLMARK_CHOLESTEROL_HOMEOSTASIS	EAG	2.5279e-03	0.1626
chr17:64321487-64323046:-	LIHC	GSVA_HALLMARK_CHOLESTEROL_HOMEOSTASIS	EER	2.5279e-03	0.1626
chr17:64321487-64323046:-	LUAD	GSVA_HALLMARK_DNA_REPAIR	EER	5.6182e-04	-0.1572
ENSG00000261371.4,PECAM1	LUAD	GSVA_HALLMARK_DNA_REPAIR	EAG	5.0090e-04	-0.1586
ENSG00000261371.4,PECAM1	OV	GSVA_HALLMARK_PROTEIN_SECRETION	EAG	1.8183e-04	-0.2503
chr17:64321487-64323046:-	OV	GSVA_HALLMARK_PROTEIN_SECRETION	EER	1.6783e-04	-0.2516
ENSG00000261371.4,PECAM1	PAAD	GSVA_HALLMARK_OXIDATIVE_PHOSPHORYLATION	EAG	1.6388e-02	-0.1828
chr17:64321487-64323046:-	PAAD	GSVA_HALLMARK_OXIDATIVE_PHOSPHORYLATION	EER	1.6388e-02	-0.1828
chr17:64321487-64323046:-	PCPG	GSVA_HALLMARK_CHOLESTEROL_HOMEOSTASIS	EER	4.5743e-02	-0.1504
ENSG00000261371.4,PECAM1	PCPG	GSVA_HALLMARK_CHOLESTEROL_HOMEOSTASIS	EAG	4.5743e-02	-0.1504
ENSG00000261371.4,PECAM1	PRAD	GSVA_HALLMARK_REACTIVE_OXYGEN_SPECIES_PATHWAY	EAG	3.0641e-02	-0.1005
chr17:64321487-64323046:-	PRAD	GSVA_HALLMARK_REACTIVE_OXYGEN_SPECIES_PATHWAY	EER	3.0641e-02	-0.1005
ENSG00000261371.4,PECAM1	READ	GSVA_HALLMARK_INTERFERON_GAMMA_RESPONSE	EAG	4.5096e-02	0.2130
chr17:64321487-64323046:-	READ	GSVA_HALLMARK_INTERFERON_GAMMA_RESPONSE	EER	4.5096e-02	0.2130
ENSG00000261371.4,PECAM1	SARC	GSVA_HALLMARK_KRAS_SIGNALING_DN	EAG	2.9004e-02	-0.1422
chr17:64321487-64323046:-	SARC	GSVA_HALLMARK_KRAS_SIGNALING_DN	EER	2.9004e-02	-0.1422
ENSG00000261371.4,PECAM1	SKCM	GSVA_HALLMARK_KRAS_SIGNALING_UP	EAG	3.7426e-02	-0.1015
chr17:64321487-64323046:-	SKCM	GSVA_HALLMARK_KRAS_SIGNALING_UP	EER	3.7426e-02	-0.1015
chr17:64321487-64323046:-	STAD	GSVA_HALLMARK_DNA_REPAIR	EER	2.5629e-04	-0.1943
ENSG00000261371.4,PECAM1	STAD	GSVA_HALLMARK_DNA_REPAIR	EAG	2.1811e-04	-0.1964
chr17:64321487-64323046:-	TGCT	GSVA_HALLMARK_OXIDATIVE_PHOSPHORYLATION	EER	5.2099e-03	-0.2484
ENSG00000261371.4,PECAM1	TGCT	GSVA_HALLMARK_OXIDATIVE_PHOSPHORYLATION	EAG	5.2099e-03	-0.2484
chr17:64321487-64323046:-	THCA	GSVA_HALLMARK_MITOTIC_SPINDLE	EER	1.4604e-02	0.1103
ENSG00000261371.4,PECAM1	THCA	GSVA_HALLMARK_MITOTIC_SPINDLE	EAG	1.4604e-02	0.1103
chr17:64321487-64323046:-	UCS	GSVA_HALLMARK_SPERMATOGENESIS	EER	2.9221e-03	0.4164
ENSG00000261371.4,PECAM1	UCS	GSVA_HALLMARK_SPERMATOGENESIS	EAG	2.9221e-03	0.4164
ENSG00000261371.4,PECAM1	UVM	GSVA_HALLMARK_PROTEIN_SECRETION	EAG	2.5259e-03	-0.4065

Top

7. Enriched editing regions and drugs for PECAM1

Correlations between enriched editing regions and drug sensitivity.

* First, the drug sensitivity (IS50) was estimated on 84 drugs by pRRophetic package.

* Second, the correlations between editing enriched regions and drug sensitivity were analyzed (P<0.05 and Informative number >=20).

* EER: enriched editing region, EAG: EER-associated genes.

* Only shows the most significant correlation result of EERs/EAGs with the IS50 scores of 84 drugs according to correlation coefficient (R). For more results, please go to download page.

ID_events	cancer	Drug	Type	P	R	CorrelationPlot
chr17:64321487-64323046:-	BLCA	BMS.536924	EER	5.5847e-05	0.2119
ENSG00000261371.4,PECAM1	BLCA	BMS.536924	EAG	5.5847e-05	0.2119
ENSG00000261371.4,PECAM1	BRCA	BMS.708163	EAG	3.9128e-03	-0.0902
chr17:64321487-64323046:-	BRCA	BMS.708163	EER	3.9176e-03	-0.0902
ENSG00000261371.4,PECAM1	CESC	CI.1040	EAG	1.6528e-02	0.1503
chr17:64321487-64323046:-	CESC	CI.1040	EER	1.6528e-02	0.1503
ENSG00000261371.4,PECAM1	CHOL	AZD6482	EAG	3.6785e-03	-0.5060
ENSG00000261371.4,PECAM1	COAD	CCT007093	EAG	1.7007e-03	-0.1991
chr17:64321487-64323046:-	COAD	CCT007093	EER	1.7007e-03	-0.1991
ENSG00000261371.4,PECAM1	GBM	AZD7762	EAG	1.7498e-02	-0.1999
chr17:64321487-64323046:-	GBM	AZD7762	EER	1.7498e-02	-0.1999
chr17:64321487-64323046:-	HNSC	JW.7.52.1	EER	8.0317e-04	0.1562
ENSG00000261371.4,PECAM1	HNSC	JW.7.52.1	EAG	8.0317e-04	0.1562
chr17:64321487-64323046:-	KICH	FTI.277	EER	5.2643e-03	-0.3422
ENSG00000261371.4,PECAM1	KICH	FTI.277	EAG	5.2643e-03	-0.3422
chr17:64321487-64323046:-	KIRC	CGP.60474	EER	4.7879e-08	0.2748
ENSG00000261371.4,PECAM1	KIRC	CGP.60474	EAG	4.3210e-08	0.2757
chr17:64321487-64323046:-	KIRP	AICAR	EER	4.4081e-02	0.1267
ENSG00000261371.4,PECAM1	KIRP	AICAR	EAG	4.4081e-02	0.1267
chr17:64321487-64323046:-	LGG	FH535	EER	3.4352e-03	0.1364
ENSG00000261371.4,PECAM1	LGG	FH535	EAG	3.4352e-03	0.1364
ENSG00000261371.4,PECAM1	LIHC	Lapatinib	EAG	5.0931e-03	-0.1548
chr17:64321487-64323046:-	LIHC	Lapatinib	EER	5.0931e-03	-0.1548
ENSG00000261371.4,PECAM1	LUAD	GW843682X	EAG	1.1290e-03	0.1485
chr17:64321487-64323046:-	LUAD	GW843682X	EER	1.2099e-03	0.1476
ENSG00000261371.4,PECAM1	LUSC	ABT.888	EAG	2.0589e-02	0.1079
chr17:64321487-64323046:-	LUSC	ABT.888	EER	2.0589e-02	0.1079
ENSG00000261371.4,PECAM1	MESO	Midostaurin	EAG	9.3732e-03	-0.3152
chr17:64321487-64323046:-	MESO	Midostaurin	EER	9.3732e-03	-0.3152
ENSG00000261371.4,PECAM1	OV	GW843682X	EAG	2.1593e-03	-0.2062
chr17:64321487-64323046:-	OV	GW843682X	EER	2.0218e-03	-0.2075
ENSG00000261371.4,PECAM1	PAAD	AZD6482	EAG	1.2396e-03	-0.2493
chr17:64321487-64323046:-	PAAD	AZD6482	EER	1.2396e-03	-0.2493
chr17:64321487-64323046:-	PRAD	AZD7762	EER	4.2386e-02	0.0944
ENSG00000261371.4,PECAM1	PRAD	AZD7762	EAG	4.2386e-02	0.0944
chr17:64321487-64323046:-	READ	Gefitinib	EER	7.4565e-03	-0.2818
ENSG00000261371.4,PECAM1	READ	Gefitinib	EAG	7.4565e-03	-0.2818
chr17:64321487-64323046:-	SARC	Cyclopamine	EER	2.7286e-02	-0.1437
ENSG00000261371.4,PECAM1	SARC	Cyclopamine	EAG	2.7286e-02	-0.1437
chr17:64321487-64323046:-	SKCM	FH535	EER	4.4597e-03	-0.1383
ENSG00000261371.4,PECAM1	SKCM	FH535	EAG	4.4597e-03	-0.1383
chr17:64321487-64323046:-	STAD	JNK.Inhibitor.VIII	EER	1.1474e-02	-0.1350
ENSG00000261371.4,PECAM1	STAD	JNK.Inhibitor.VIII	EAG	1.0498e-02	-0.1366
chr17:64321487-64323046:-	TGCT	GDC0941	EER	6.6871e-03	-0.2414
ENSG00000261371.4,PECAM1	TGCT	GDC0941	EAG	6.6871e-03	-0.2414
ENSG00000261371.4,PECAM1	THCA	Docetaxel	EAG	4.9957e-05	0.1822
chr17:64321487-64323046:-	THCA	Docetaxel	EER	4.9957e-05	0.1822
ENSG00000261371.4,PECAM1	THYM	BMS.708163	EAG	4.8110e-03	-0.2758
ENSG00000261371.4,PECAM1	UCEC	Cisplatin	EAG	1.6646e-02	-0.2000
chr17:64321487-64323046:-	UCEC	Cisplatin	EER	1.6646e-02	-0.2000
ENSG00000261371.4,PECAM1	UCS	Embelin	EAG	1.8115e-02	-0.3364
chr17:64321487-64323046:-	UCS	Embelin	EER	1.8115e-02	-0.3364
ENSG00000261371.4,PECAM1	UVM	BMS.708163	EAG	1.4318e-03	0.4269

Top

EAGs targeted by drugs from DrugBank database.

* EAG: EER-associated genes.

EER

ENST

UniprotID

DrugBankID

Drug

DrugType